These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29286931)

  • 1. Newborn drug testing practices in Iowa birthing hospitals.
    Wood KE; Smith P; Krasowski MD
    J Neonatal Perinatal Med; 2017; 10(4):445-450. PubMed ID: 29286931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal illicit drug screening practices in Iowa: the impact of utilization of a structured screening protocol.
    Oral R; Strang T
    J Perinatol; 2006 Nov; 26(11):660-6. PubMed ID: 17036035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staff training makes a difference: improvements in neonatal illicit drug testing and intervention at a tertiary hospital.
    Oral R; Koc F; Jogerst K; Bayman L; Austin A; Sullivan S; Bayman EO
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1049-54. PubMed ID: 24060204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening, testing, and reporting for drug and alcohol use on labor and delivery: a survey of Maryland birthing hospitals.
    Miller C; Lanham A; Welsh C; Ramanadhan S; Terplan M
    Soc Work Health Care; 2014; 53(7):659-69. PubMed ID: 25133299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance use in pregnancy.
    Wong S; Ordean A; Kahan M; ; ; ; ;
    J Obstet Gynaecol Can; 2011 Apr; 33(4):367-384. PubMed ID: 21501542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perinatal screening for illicit drugs: policies in hospitals in a large metropolitan area.
    Birchfield M; Scully J; Handler A
    J Perinatol; 1995; 15(3):208-14. PubMed ID: 7666270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial Disparities in Newborn Drug Testing After Implementation of Question-Based Screening for Prenatal Substance Use.
    Soos A; Plegue M; Darwiche A; Oshman L; Frank CJ
    Obstet Gynecol; 2024 Aug; 144(2):233-240. PubMed ID: 38843536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perinatal substance abuse: the impact of reporting infants to child protective services.
    MacMahon JR
    Pediatrics; 1997 Nov; 100(5):E1. PubMed ID: 9346995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing a perinatal substance abuse screening tool.
    Wallman CM; Smith PB; Moore K
    Adv Neonatal Care; 2011 Aug; 11(4):255-67. PubMed ID: 22123347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Racism in Newborn Drug Testing: Perspectives of Health Care and Child Protective Services Professionals.
    Shetty C; Oshman L; Costa A; Waidley V; Madlambayan E; Joassaint M; McCabe K; Townsel C; Wu JP; Frank CJ; Chandanabhumma PP
    Ann Fam Med; 2024; 22(4):271-278. PubMed ID: 39038971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A search for guidance: examining prenatal substance exposure protocols.
    Zellman GL; Fair C; Houbé J; Wong M
    Matern Child Health J; 2002 Sep; 6(3):205-12. PubMed ID: 12236668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perinatal illicit drug screening practices in mother-newborn dyads at a university hospital serving rural/semi-urban communities: translation of research to quality improvement.
    Oral R; Koc F; Bayman EO; Assad A; Austin A; Strang T; Bayman L
    J Matern Fetal Neonatal Med; 2012 Nov; 25(11):2441-6. PubMed ID: 22716202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive toxicology screening in newborns: ethical issues in the decision to legally intervene.
    Burns DL
    Pediatr Nurs; 1997; 23(1):73-5; discussion 76-8, 86. PubMed ID: 9137025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Illicit drug exposure in patients evaluated for alleged child abuse and neglect.
    Oral R; Bayman L; Assad A; Wibbenmeyer L; Buhrow J; Austin A; Bayman EO
    Pediatr Emerg Care; 2011 Jun; 27(6):490-5. PubMed ID: 21629147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for out-of-home custody child care among families with alcohol and substance abuse problems.
    Sarkola T; Kahila H; Gissler M; Halmesmäki E
    Acta Paediatr; 2007 Nov; 96(11):1571-6. PubMed ID: 17850394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-Based Newborn Drug Testing in a Setting With a Low Prevalence of Maternal Drug Use.
    Wood KE; McMillin GA; Krasowski MD
    Hosp Pediatr; 2019 Aug; 9(8):593-600. PubMed ID: 31278167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A national survey of state maternal and newborn drug testing and reporting policies.
    Adirim TA; Sen Gupta N
    Public Health Rep; 1991; 106(3):292-6. PubMed ID: 1905050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the incidence of substance exposed newborns with child welfare system involvement.
    Durrance CP; Atkins DN
    Child Abuse Negl; 2024 Mar; 149():106629. PubMed ID: 38232502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug screening in newborns and mothers using meconium samples, paired urine samples, and interviews.
    Bibb KW; Stewart DL; Walker JR; Cook VD; Wagener RE
    J Perinatol; 1995; 15(3):199-202. PubMed ID: 7666268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Newborn Drug Testing and Variations by Birthing Parent Race and Ethnicity Before and After Recreational Cannabis Legalization.
    Schoneich S; Plegue M; Waidley V; McCabe K; Wu J; Chandanabhumma PP; Shetty C; Frank CJ; Oshman L
    JAMA Netw Open; 2023 Mar; 6(3):e232058. PubMed ID: 36884249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.